Why format complicates fair balance

Sessions on social media promotion have become common at regulatory affairs conferences because existing promotional standards were written for materials that do not resemble a post, a comment thread, or a video clip. Regulators in different jurisdictions have had to apply those standards to formats with limited space and changing layouts.

Fair balance is a recurring problem. Promotional material for a prescription product is generally expected to present risk information alongside benefit claims. That expectation becomes harder to meet when a platform limits the number of available characters or places additional text behind a click.

A short post may leave little room for both sides of the product information. A company may shorten the benefit claim, compress the risk information, or send readers to another page. Each option raises the question of whether the audience receives the context that promotional standards expect to accompany the claim.

The FDA has addressed character-space-limited platforms in draft guidance on promotion in social media. Other regulators have reached broadly similar conclusions about the limits of links. A link can give readers access to additional material, but it may not replace risk information that should appear alongside a benefit claim.

The issue concerns more than the accuracy of one sentence. It also concerns whether the format gives the audience the information expected to accompany the claim. A platform’s design affects how much context appears in the initial message and how much effort readers must make to locate additional information.

Responsibility for third-party content

Third-party content creates a separate problem. A company does not control everything users write, including comments, posts, or videos. A company can become responsible for material it prompts, funds, or endorses.

That boundary matters because user content may appear independent while still being connected to the company. Material that a company encourages, pays for, or approves may receive different treatment from content created without the company’s involvement. The source of the material and the company’s role in its creation become important parts of the promotional question.

The distinction can be difficult to apply. A company may participate on a platform where users discuss its product without creating every contribution. It may also decide whether to encourage a certain type of content or endorse something a user has said. Those actions can affect whether the material remains ordinary user discussion or becomes connected to promotion.

Responses to inaccurate posts create another boundary. A company may want to correct misinformation about its own product. The line between correcting misinformation and promoting a product can be thin under FDA compliance and enforcement standards. A response may draw attention to the product or introduce benefit claims while addressing the original post.

Jurisdictions differ in how far a company may go when responding to inaccurate posts about its own product. An approach that fits one jurisdiction may not fit another. The difference becomes more significant when the response is visible outside the market where it was written.

National rules for global visibility

Territory is another recurring issue. A post may be visible in many places, while promotional rules are national. A product approved in one country may be unapproved in another, even when people in both countries can see the same message.

This creates a mismatch between a platform’s reach and the scope of FDA rulemaking in the Federal Register. A company may prepare a post for one jurisdiction, but the platform may not limit that post to that jurisdiction. Viewers elsewhere may encounter the same benefit claim, risk information, and product reference under different national rules.

Sharing can widen the mismatch. A post may move beyond its original audience, and the rules governing promotion may differ in the place where a new viewer sees it. The issue is not limited to wording. It may also concern whether the product is approved in that country and whether promotion is permitted there.

The three problems are connected. A global audience may see a short message with limited room for risk information. Users may add content that a company did not create, while the company decides whether to prompt, fund, endorse, or correct it. National rules then apply to material that can cross borders without the platform changing its format.

Evaluating claims under compressed formats

These policy issues also matter to people assessing promotional claims. A short message may present a benefit without the surrounding information that would normally help a reader evaluate it. A link may provide more detail, but readers still have to find it, open it, and connect it to the claim that first drew their attention.

The same concern applies when people compare online treatment options. Price and service claims may appear alongside product-related promotion, while the format leaves limited space for information needed for comparison. The relevant question is what the post promises and whether the available information includes documented pricing and service terms.

Marketing claims require careful review from the buying side. The telehealth clinic reviews focused on documented pricing and service terms use that approach rather than treating social media presentation as proof of value. When promotional formats compress information, visibility does not establish completeness.